Matsunami 1990.
Methods | Randomised, parallel‐arm study Number of centres not stated Period of inclusion not stated |
|
Participants |
Inclusion criteria
Exclusion criteria Not stated Baseline data: participants were randomly divided into 2 groups: Re (+) (n = 10) and Re (‐) (n = 10)
Withdrawal: unclear |
|
Interventions |
Intervention 1 A: etretinate 1 mg/kg for 4 weeks, then 0.5 mg/kg (10 participants) Intervention 2 B: no treatment (10 participants) Co‐interventions: PUVA therapy once per week on the right side (for 12 weeks) Duration of treatment: 12 weeks |
|
Outcomes | No primary or secondary outcome pre‐specified ‐ Degree of severity based on various factors with the conclusion of no change, beginning of resolution, or complete clearance |
|
Notes | Funding: not reported | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Quote: "The patients were randomly divided into two groups" Comment: insufficient information about the sequence generation process to permit judgement |
Allocation concealment (selection bias) | Unclear risk | Comment: no information on method to guarantee allocation concealment |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Comment: no mention of blinding and etretinate side effects making blinding impossible |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Comment: no mention of blinding and etretinate side effects making blinding impossible |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Comment: no mention of missing data |
Selective reporting (reporting bias) | Unclear risk | Comment: no protocol found to guarantee that all planned outcomes are presented in the results |